Linked Life Data

18717644

Source:http://linkedlifedata.com/resource/pubmed/id/18717644

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18717644rdf:typepubmed:Citationlld:pubmed
pubmed-article:18717644lifeskim:mentionsumls-concept:C1510487lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C0006826lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C0011209lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C1295392lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C0051298lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C1417138lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:18717644lifeskim:mentionsumls-concept:C0752549lld:lifeskim
pubmed-article:18717644pubmed:issue9lld:pubmed
pubmed-article:18717644pubmed:dateCreated2008-9-17lld:pubmed
pubmed-article:18717644pubmed:abstractTextMetastasis is a key aspect of tumor malignancy, and several malignant tumors show expression of various mature N-type glycans. In particular, beta1-6 branching N-acetylglucosamine (GlcNAc) is abundantly expressed as a part of high-mannose glycans in various highly metastatic cancers. Phaseolus vulgaris agglutinin-L(4) isolectin (L(4)-PHA), which adheres to beta1-6 GlcNAc specifically, has been used for in situ cancer diagnosis. Bionanocapsules (BNCs), hollow particles with a diameter of approximately 80 nm and composed of hepatitis B surface antigen (HBsAg) and a lipid bilayer, have been developed as human liver-specific nanocapsules for in vivo drug delivery system. In this study, we have generated L(4)-PHA-displaying BNCs (PHA-BNCs) and examined whether L(4)-PHA could retarget the BNCs to malignant tumors as a "biosensor" distinguishing tumor metastaticity. Fluorescence-labeled PHA-BNCs injected systemically into a mouse xenograft model were found to accumulate in beta1-6 GlcNAc-expressing malignant tumors. The PHA-BNCs were able to deliver DNA to the malignant cancer cells. These results open up the possibility of using L(4)-PHA lectin as a targeting molecule in a drug delivery system, and of using PHA-BNCs as a novel nanodevice for malignant tumor-specific bioimaging and drug delivery.lld:pubmed
pubmed-article:18717644pubmed:languageenglld:pubmed
pubmed-article:18717644pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18717644pubmed:citationSubsetIMlld:pubmed
pubmed-article:18717644pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18717644pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18717644pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18717644pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18717644pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18717644pubmed:statusMEDLINElld:pubmed
pubmed-article:18717644pubmed:monthSeplld:pubmed
pubmed-article:18717644pubmed:issn1557-7422lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:OkajimaToshih...lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:KurodaShun'ic...lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:TanizawaKatsu...lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:MiyoshiEijiElld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:MatsuzakiTaka...lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:TatematsuKenj...lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:KadoyaHiroyas...lld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:JungJooheeJlld:pubmed
pubmed-article:18717644pubmed:authorpubmed-author:KasuyaTakeshi...lld:pubmed
pubmed-article:18717644pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18717644pubmed:volume19lld:pubmed
pubmed-article:18717644pubmed:ownerNLMlld:pubmed
pubmed-article:18717644pubmed:authorsCompleteYlld:pubmed
pubmed-article:18717644pubmed:pagination887-95lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:meshHeadingpubmed-meshheading:18717644...lld:pubmed
pubmed-article:18717644pubmed:year2008lld:pubmed
pubmed-article:18717644pubmed:articleTitleIn vivo delivery of bionanocapsules displaying Phaseolus vulgaris agglutinin-L4 isolectin to malignant tumors overexpressing N-acetylglucosaminyltransferase V.lld:pubmed
pubmed-article:18717644pubmed:affiliationDepartment of Structural Molecular Biology, Institute of Scientific and Industrial Research, Osaka University, Ibaraki, Osaka 567-0047, Japan.lld:pubmed
pubmed-article:18717644pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18717644pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed